India Pharmaceutical Industry Research 2024: $105+ Billion Market Trends, Regional Insights, Competition, Forecasts and Opportunities, 2020-2030
September 11, 2024 11:50 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "India Pharmaceutical Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
September 11, 2024 01:04 ET
|
Regeneron Pharmaceuticals, Inc.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is...
ViaDerma Completes First Shipment of 500,000 Units to Nigeria
September 10, 2024 08:00 ET
|
ViaDerma, Inc.
LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC: VDRM), a specialty pharmaceutical company known for developing innovative transdermal drug delivery systems, is pleased to...
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
BioNTX Unveils 2024 Rising Stars at the iC³® Life Science & Healthcare Innovation Summit
September 05, 2024 11:06 ET
|
BioNTX
IRVING, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- As Texas continues to grow as a biotech and healthcare innovative hub, BioNTX is honored to announce the 2024 Rising Stars, a select group of...
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
September 05, 2024 09:00 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an...
Yseop Joins Veeva’s AI Partner Program to Accelerate Regulatory Document Writing and AI-Driven Content Automation
September 05, 2024 09:00 ET
|
Yseop
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Yseop, a leader in artificial intelligence (AI) enterprise software, is excited to announce it has joined the Veeva AI Partner Program. As a Veeva AI...
Next Generation Sequencing Market is Anticipated to Attain USD 92.2 Billion in Revenue by 2033 , at a CAGR 23.8%: Insights by Dimension Market Research
September 04, 2024 11:36 ET
|
Dimension Market Research
New York, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Overview The Global Next Generation Sequencing Market size is expected to reach USD 13.5 billion by 2024 and it is further anticipated to reach a...
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference